Jazz Pharmaceuticals Plc - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated August 17, 2017, reports the closing of a private placement of exchangeable senior notes by Jazz Pharmaceuticals Plc (the "Company") and its wholly-owned subsidiary, Jazz Investments I Limited (the "Issuer"). The transaction closed on August 23, 2017.
Key Financial Metrics and Transaction Details
- Offering Size: $500.0 million aggregate principal amount of 1.50% exchangeable senior notes due 2024.
- Over-Allotment Option: Initial purchasers hold a 13-day option to purchase up to an additional $75.0 million.
- Net Proceeds: Estimated at approximately $486.0 million, or $559.1 million if the over-allotment option is fully exercised.
- Interest Rate: 1.50% per year, payable semi-annually in cash.
- Maturity Date: August 15, 2024.
- Exchange Price: Initial exchange rate of 4.5659 ordinary shares per $1,000 principal amount (approx. $219.02 per share).
- Existing Debt: As of June 30, 2017, $500.0 million was outstanding under the Company's revolving credit facility at an interest rate of 2.91%.
Material Changes and Use of Proceeds
The primary material change is the addition of new long-term debt obligations. The Company intends to use the net proceeds to repay all or a substantial portion of the outstanding borrowings under its revolving credit facility. Any remaining proceeds will be used for general corporate purposes, including potential business development activities. This transaction replaces higher-cost revolving credit debt (2.91%) with lower-cost exchangeable notes (1.50%).
Outlook, Risks, and Contingencies
Management Commentary: The notes are fully and unconditionally guaranteed by the Company on a senior unsecured basis. Settlement upon exchange may be in cash, ordinary shares, or a combination, at the Issuer's election.
Risks and Contingencies:
- Execution Risk: Uncertainty regarding whether initial purchasers will exercise the option to purchase additional notes.
- Liquidity Risk: The Company's ability to repay outstanding borrowings under the revolving credit facility in a timely manner.
- Accounting Risk: The accounting method for exchangeable debt securities settled in cash could materially affect reported financial results.
- Market Risk: Changes in credit ratings could adversely affect the market price of ordinary shares and the value of the notes.
- Events of Default: Includes failure to pay interest or principal, failure to comply with covenants, and bankruptcy events, which could trigger acceleration of the debt.
Investor Verification Checklist
- Verify the final exercise status of the $75.0 million over-allotment option.
- Confirm the exact amount of revolving credit facility debt repaid using the net proceeds.
- Review the full text of the Indenture (Exhibit 4.1) for specific covenants and exchange mechanics.
- Monitor the Company's credit rating and its impact on the exchange price and note valuation.
- Assess the Company's cash flow sufficiency to service the new debt and any remaining credit facility obligations.